Back

Recurrent pre-leukemic deletions in myeloid malignancies are the result of DNA double-strand breaks followed by microhomology-mediated end joining

Feldman, T.; Bercovich, A.; Moskovitz, Y.; Chapal-Ilani, N.; Mitchell, A.; Medeiros, J. J.; Kaushansky, N.; Biezuner, T.; Minden, M. D.; Gupta, V.; Tanay, A.; Shlush, L. I.

2020-01-02 genomics
10.1101/2020.01.01.888610 bioRxiv
Show abstract

The mechanisms underlying myeloid malignancies deletions are not well understood, nor is it clear why specific genomic hotspots are predisposed to particular deletions. In the current study we inspected the genomic regions around recurrent deletions in myeloid malignancies, and identified microhomology-mediated end-joining (MMEJ) signatures in recurrent deletions in CALR, ASXL1 and SRSF2 loci. Since MMEJ deletions are the result of DNA double-strand breaks (DSBs), we introduced CRISPR Cas9 DSBs into exon 12 of ASXL1, successfully generating recurrent ASXL1 deletion in human hematopoietic stem and progenitor cells (HSPCs). A systematic search of COSMIC dataset for MMEJ deletions in all cancers revealed that recurrent deletions enrich myeloid malignancies. Despite this myeloid predominance, we provide evidence that MMEJ deletions occur in multipotent HSCs. An analysis of DNA repair pathway gene expression in single human adult bone marrow HSPCs could not identify a subpopulation of multipotent HSPCs with increased MMEJ expression, however exposed differences between myeloid and lymphoid biased progenitors. Our data indicate an association between MMEJ-repaired DSBs and recurrent MMEJ deletions in human HSCs and in myeloid leukemia. A better understanding of the source of these DSBs and the regulation of the HSC MMEJ repair pathway might aid with preventing recurrent deletions in human pre-leukemia.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
Experimental Hematology
11 papers in training set
Top 0.1%
15.2%
2
Frontiers in Genetics
197 papers in training set
Top 0.2%
10.8%
3
eLife
5422 papers in training set
Top 10%
7.4%
4
Scientific Reports
3102 papers in training set
Top 13%
7.0%
5
Nature Communications
4913 papers in training set
Top 31%
5.0%
6
Nucleic Acids Research
1128 papers in training set
Top 5%
4.1%
7
Leukemia
39 papers in training set
Top 0.4%
2.4%
50% of probability mass above
8
PLOS Genetics
756 papers in training set
Top 7%
2.1%
9
Cells
232 papers in training set
Top 2%
1.9%
10
Cell Reports
1338 papers in training set
Top 22%
1.8%
11
Cancers
200 papers in training set
Top 3%
1.8%
12
EMBO reports
136 papers in training set
Top 2%
1.7%
13
Epigenetics
43 papers in training set
Top 0.5%
1.5%
14
Communications Biology
886 papers in training set
Top 13%
1.3%
15
Genome Biology
555 papers in training set
Top 6%
1.1%
16
Cell Death Discovery
51 papers in training set
Top 0.9%
1.0%
17
Journal of Hematology & Oncology
10 papers in training set
Top 0.1%
1.0%
18
Journal of Cellular and Molecular Medicine
18 papers in training set
Top 0.6%
1.0%
19
BMC Medical Genomics
36 papers in training set
Top 0.9%
0.9%
20
PLOS ONE
4510 papers in training set
Top 63%
0.9%
21
Genome Medicine
154 papers in training set
Top 7%
0.9%
22
BMC Biology
248 papers in training set
Top 3%
0.9%
23
Frontiers in Immunology
586 papers in training set
Top 7%
0.8%
24
International Journal of Molecular Sciences
453 papers in training set
Top 15%
0.8%
25
EMBO Molecular Medicine
85 papers in training set
Top 4%
0.8%
26
Haematologica
24 papers in training set
Top 0.4%
0.8%
27
Science Advances
1098 papers in training set
Top 29%
0.8%
28
Clinical Cancer Research
58 papers in training set
Top 2%
0.8%
29
Oncogene
76 papers in training set
Top 2%
0.7%
30
Life Science Alliance
263 papers in training set
Top 2%
0.7%